Trial Profile

A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Raltegravir (Primary) ; Efavirenz; Emtricitabine/tenofovir disoproxil fumarate
Indications HIV-1 infections
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms STARTMRK
Sponsors Merck & Co; Merck Sharp & Dohme

16 May 2019 This trial has been completed in Spain as per European Clinical Trials Database record.
09 Sep 2014 Results of a racial subgroup analysis on the efficacy and safety of raltegravir presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy.
13 Sep 2013 Results for Latin American patients presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com